Complicated intra-abdominal infections (cIAIs) are tissue-invasive infections leading to abscess formation or generalized peritonitis. The management of cIAIs involves operative or percutaneous intervention to obtain surgical control of the source. Nonetheless, patients with cIAIs are at risk of sepsis and mortality \[[@CIV097C1]--[@CIV097C4]\].

Empiric antimicrobial therapy with appropriate agents is an important component of treatment \[[@CIV097C5], [@CIV097C6]\]. Initial empiric therapy that is not effective against infecting pathogens increases costs, treatment failure, and death \[[@CIV097C7]--[@CIV097C10]\]. Because of this, cIAIs are an important infection category for evaluation of the efficacy of investigational agents.

The well-recognized appearance of antimicrobial resistance among gram-negative bacteria has stimulated the development of novel agents \[[@CIV097C11]\], particularly those targeting Enterobacteriaceae that produce extended-spectrum β-lactamases (ESBLs) \[[@CIV097C12]\], which confer resistance to most β-lactam antimicrobial agents \[[@CIV097C1]\].

Ceftolozane/tazobactam consists of a novel cephalosporin and an established β-lactamase inhibitor that is being developed to address antimicrobial resistance in serious infections caused by gram-negative pathogens, including cIAI, complicated urinary tract infection/pyelonephritis (cUTI), and ventilated nosocomial pneumonia. In vitro activity of ceftolozane/tazobactam has been confirmed against ESBL-producing Enterobacteriaceae, drug-resistant *Pseudomonas aeruginosa* \[[@CIV097C13]--[@CIV097C16]\], and some *Streptococcus* species \[[@CIV097C17]\]. The results from a phase 2 study with ceftolozane/tazobactam in combination with metronidazole in cIAI supported further development for this indication \[[@CIV097C18]\].

We now report the results from ASPECT-cIAI (Assessment of the Safety Profile and Efficacy of Ceftolozane/Tazobactam in Complicated Intra-abdominal Infections), a large global phase 3 clinical program that evaluated intravenous ceftolozane/tazobactam plus metronidazole vs meropenem for the treatment of hospitalized adult patients with cIAI.

PATIENTS AND METHODS {#s2}
====================

Study Design {#s2a}
------------

Two identical multicenter, prospective, randomized, double-blind, placebo-controlled trials were initiated in December 2011 at 196 study centers worldwide (ClinicalTrials.gov identifiers NCT01445665 and NCT01445678).

The trials were designed in compliance with current clinical guidelines and the regulatory requirements of the US Food and Drug Administration (FDA) and the European Medicines Agency, approved by local institutional review boards, and conducted in accordance with the International Conference on Harmonisation/Good Clinical Practice guidelines and the principles of the Declaration of Helsinki. All patients were required to provide written informed consent prior to participation. In 2012, the FDA released a draft guidance providing for a single study pathway for approval of antibiotics in cUTI and cIAI \[[@CIV097C19]\]. The sponsor sought and received prospective permission from the relevant regulatory agencies to pool the data from the 2 protocols upon completion to form a single dataset for analysis. Enrollment in the 2 protocols was completed in September 2013, and data were pooled after database lock in each study.

Inclusion Criteria {#s2b}
------------------

Patients were to be ≥18 years of age, with clinical evidence of cIAI. Operative or percutaneous drainage of an infectious focus was either planned or had been performed recently (within 24 hours), confirming the presence of cIAI.

Exclusion Criteria {#s2c}
------------------

The following exclusions applied: cIAI managed by staged abdominal repair in which the fascia was not closed; low likelihood of adequate source control at surgery; creatinine clearance \<30 mL/minute; or use of systemic antimicrobial therapy for IAI for \>24 hours prior to the first dose of study drug (unless this treatment failed, defined by the need for additional intervention and persistent signs of ongoing infection with a positive culture of intra-abdominal abscess or peritonitis fluid, despite \>48 hours of prior antimicrobial therapy).

Randomization and Treatment {#s2d}
---------------------------

Randomization numbers were computer-generated. Patients were assigned (1:1) by the study site\'s pharmacist to intravenous ceftolozane/tazobactam 1.5 g (containing 1 g ceftolozane and 500 mg tazobactam) plus metronidazole (500 mg every 8 hours) or intravenous meropenem (1 g every 8 hours) plus placebo for 4--10 days. Treatment could be continued for up to 14 days in patients who had 1 of the following: multiple abscesses; non-appendix-related diffuse peritonitis, failure of prior antimicrobial therapy, or hospital-acquired infection. The dose of ceftolozane/tazobactam was based on data from previous clinical studies \[[@CIV097C18], [@CIV097C20]\]. The comparator, meropenem, is recommended by the Surgical Infection Society and the Infectious Diseases Society of America as appropriate first-line empiric therapy for high-risk and severe cIAI, and is prescribed commonly for this indication \[[@CIV097C5], [@CIV097C6]\]. In patients with moderate renal impairment (creatinine clearance, 30--50 mL/minute), the ceftolozane/tazobactam dose was reduced to 750 mg every 8 hours and the meropenem dose to 1 g every 12 hours. Placebo saline infusions were used to maintain blinding. Drug assignment was concealed from the patient and all clinical and study staff.

Assessments {#s2e}
-----------

At baseline, intra-abdominal specimens were collected from aspirates (collected with a needle or a syringe) for culture of aerobes and anaerobes. Samples were inoculated into aerobic and anaerobic culture bottles, incubated at 35°C--37°C, and transferred to the microbiology laboratory. Signs and symptoms of the index infection were recorded daily. Blood samples for culture were drawn in patients with hospital-acquired infections, those who had failed prior antimicrobial therapy, and those with signs of severe sepsis \[[@CIV097C21]\]. Other baseline assessments included measurement of disease severity, as determined by the Acute Physiology and Chronic Health Evaluation (APACHE) II score; measurements of hematology, chemistry, and coagulation; urinalysis; and estimation of creatinine clearance.

Outcome Assessment {#s2f}
------------------

Clinical outcomes were assessed at the end of therapy (within 24 hours of last dose of treatment), the test-of-cure (TOC) visit (24--32 days after start of therapy), and the late follow-up visit (38--45 days after start of therapy). Clinical cure was defined as complete resolution or significant improvement in signs and symptoms of the index infection, such that no additional antimicrobials or interventions were required. Events defining clinical failure included death due to cIAI prior to the TOC visit, persisting or recurrent infection requiring additional intervention, treatment with additional antimicrobials for ongoing symptoms of IAI, and/or surgical site infection \[[@CIV097C22]\]. An indeterminate response was recorded when trial data were not available for evaluation of efficacy for any reason, including death unrelated to the index infection, or in extenuating circumstances that precluded classification as cure or failure. Analysis populations are defined in [Supplementary Table 1](http://cid.oxfordjournals.org/lookup/suppl/doi:10.1093/cid/civ097/-/DC1). Patients with missing clinical outcome data or indeterminate responses were considered to have failed treatment in the intent-to-treat (ITT) and microbiological ITT (MITT) analyses, but were excluded from the per-protocol (clinically evaluable \[CE\] and microbiologically evaluable \[ME\]) analyses.

Pathogen susceptibility to ceftolozane/tazobactam was defined as a minimum inhibitory concentration (MIC) ≤8 mg/L, intermediate as an MIC of 16 mg/L, and resistant as an MIC ≥32 mg/L. MIC cutoffs for determination of susceptibility to meropenem were based on Clinical Laboratory Standards Institute (CLSI) definitions. Enterobacteriaceae susceptibility was defined as MIC ≤1 mg/L, intermediate as MIC 2 mg/L, and resistant as MIC ≥4 mg/L. For *P. aeruginosa*, the MIC cutoffs were ≤2 mg/L, 4 mg/L, and ≥8 mg/L, respectively \[[@CIV097C23]\]. Multidrug resistance in *P. aeruginosa* was based on the CLSI breakpoints and was defined as resistance or nonsusceptibility to ≥3 drug classes that are known to be active against *P. aeruginosa*. Enterobacteriaceae organisms with an ESBL phenotype (predefined criteria: MIC ≥2 mg/L for any cephalosporin, ≥3 dilution change in MIC when an antibiotic was combined with a β-lactamase inhibitor) identified prior to database lock were characterized by JMI Laboratories (North Liberty, Iowa) using a commercial MicroArray System Check-MDR CT101 kit (Check-points, Wageningen, the Netherlands). Safety was assessed by review of adverse events (AEs), vital signs, physical examination findings, and clinical laboratory results.

Source Control Review {#s2g}
---------------------

All patients with a baseline pathogen and an investigator-assigned outcome of failure, and those with an outcome of clinical cure who underwent a second procedure, were reviewed by an independent blinded surgical review panel comprising 3 surgeons and 2 radiologists. Source control was considered adequate when the physical and mechanical measures were consistent with current local standards of practice to eliminate the source of infection, control ongoing contamination, and restore gastrointestinal function \[[@CIV097C24]\]. Patients who were considered to have had inadequate source control were excluded from the per-protocol analyses.

Statistical Analysis {#s2h}
--------------------

Prior to completion of the studies, statistical analyses were planned based on pooled data from the 2 trials. The planned pooled sample size ensured a minimum of 90% power to demonstrate the noninferiority of ceftolozane/tazobactam plus metronidazole to meropenem at a 10% noninferiority margin at a 1-sided significance level of 0.025. These calculations also assumed that 80% of randomized patients would meet the criteria to be included in the MITT population and that the clinical cure rate in both arms would be 75%.

The noninferiority hypothesis was tested through a 2-sided 95% confidence interval (CI) approach. The weighted difference in cure rates and the 95% CI around the difference in cure rates between study treatments were calculated using a stratified Newcombe CI with minimum risk weights \[[@CIV097C25], [@CIV097C26]\]. If the lower bound of the 95% CI for the difference (ceftolozane/tazobactam plus metronidazole minus meropenem) was above −10 percentage points, noninferiority was claimed.

Other secondary endpoints of clinical cure in the ITT and CE populations, various ME population subgroups, and per-baseline pathogen in the ME population were analyzed using a 95% CI calculated by the Wilson score methodology. Safety and tolerability of ceftolozane/tazobactam plus metronidazole were also evaluated. Statistical analyses were performed using SAS version 9.1.3 or higher (SAS Institute, Cary, North Carolina).

RESULTS {#s3}
=======

Patient Disposition and Baseline Characteristics {#s3a}
------------------------------------------------

In total, 993 patients were randomized to ceftolozane/tazobactam plus metronidazole (n = 487) or meropenem (n = 506), and 806 (81.2%) qualified for the MITT population (Figure [1](#CIV097F1){ref-type="fig"}). Approximately 50% of patients in each treatment group received therapy for up to 7 days, and an additional 36.5% received treatment for up to 10 days. The mean duration of treatment for patients who were eligible to continue therapy beyond 10 days is shown in Table [1](#CIV097TB1){ref-type="table"}. Table 1.Duration of Therapy for Patients Who Were Eligible for Extension of Treatment Beyond 10 Days (Microbiological Intent-to-Treat Population)DiagnosisMean Duration of Therapy, dMin--Max, dMultiple abscess (n = 64)9.62--15Diffuse peritonitis, nonappendix (n = 149)8.62--15Failed prior therapy, nonappendix (n = 42)9.32--15Localized complicated appendicitis (n = 254)^a^7.02--15[^2] Figure 1.Patient disposition in ASPECT-cIAI (Assessment of the Safety Profile and Efficacy of Ceftolozane/Tazobactam in Complicated Intra-abdominal Infections). ^a^Patients could be excluded for more than one reason. Abbreviations: BIP, baseline infecting pathogen; CE, clinically evaluable; MITT, microbiological ITT.

The majority of participants were from Europe (76.9%), followed by South America (10.5%), North America (7.6%), and other geographic regions (5.0%). A list of participating investigators and their sites is provided in the [Supplementary Data](http://cid.oxfordjournals.org/lookup/suppl/doi:10.1093/cid/civ097/-/DC1). Baseline demographic characteristics were similar between treatment groups (Table [2](#CIV097TB2){ref-type="table"}). The most common origin of infection was the appendix, and the most common diagnosis was appendiceal perforation or abscess (Table [3](#CIV097TB3){ref-type="table"}). Table 2.Baseline Demographics (Microbiological Intent-to-Treat Population)CharacteristicCeftolozane/Tazobactam Plus Metronidazole (n = 389)Meropenem (n = 417)Sex, male, No. (%)218 (56.0)248 (59.5)Race, white, No. (%)367 (94.3)388 (93.0)Age, y Mean (SD)50.8 (18.3)50.4 (16.9) 18--64, No. (%)289 (74.3)332 (79.6) 65--74, No. (%)54 (13.9)48 (11.5) ≥75, No. (%)46 (11.8)37 (8.9)Body mass index, kg/m^2^, mean (SD)26.76 (5.5)27.07 (5.3)Baseline APACHE II score, No. (%)^a^ Mean (SD)6.2 (4.2)6.0 (4.1) 0--5191 (49.2)213 (51.1) 6--10143 (36.9)153 (36.7) 11--1542 (10.8)38 (9.1) \>1512 (3.1)13 (3.1)Presence of bacteremia8 (2.1)12 (2.9)Creatinine clearance, No. (%) Mild renal impairment (50 to 79 mL/min)98 (25.2)109 (26.1) Moderate renal impairment (30--49 mL/min)23 (5.9)13 (3.1) Severe renal impairment (\<30 mL/min)00[^3][^4] Table 3.Site of Infections, Diagnoses, Disease Characteristics, and Source Control Procedures (Microbiological Intent-to-Treat Population)CharacteristicCeftolozane/Tazobactam Plus Metronidazole (n = 389)Meropenem (n = 417)Origin of current infection, No. (%)^a^ Appendix179 (46.0)205 (49.2) Biliary--cholecystitis73 (18.8)69 (16.5) Colon56 (14.4)62 (14.9) Stomach/duodenum40 (10.3)39 (9.4) Small bowel23 (5.9)19 (4.6) Parenchymal (liver)16 (4.1)17 (4.1) Parenchymal (spleen)2 (0.5)2 (0.5) Biliary--cholangitis1 (0.3)0Diagnosis, No. (%)^b^ Appendiceal perforation or abscess175 (45.0)203 (48.7) Cholecystitis with rupture, perforation, or progression of infection72 (18.5)69 (16.5) Peritonitis due to other perforated viscus or following a prior operative procedure41 (10.5)33 (7.9) Acute gastric or duodenal perforation38 (9.8)33 (7.9) Diverticular disease with perforation or abscess29 (7.5)36 (8.6) Other IAI abscess (including liver and spleen)29 (7.5)36 (8.6) Traumatic intestinal perforation5 (1.3)7 (1.7)Abscess present, No. (%)219 (56.3)240 (57.6) Multiple abscesses^c^33 (15.1)32 (13.3)Peritonitis present, No. (%)337 (86.6)340 (81.5) Local^d^198 (58.8)203 (59.7) Diffuse^d^139 (41.2)137 (40.3)Localized complicated appendicitis, No. (%)115 (29.6)142 (34.1)Etiological mechanism, No. (%) Postoperative infection27 (6.9)28 (6.7) Trauma4 (1.0)8 (1.9) Spontaneous rupture277 (71.2)302 (72.4) Malignancy11 (2.8)13 (3.1) Other70 (18.0)66 (15.8)Procedure type, No. (%)^e^ Laparotomy274 (70.4)272 (65.2) Laparoscopy86 (22.1)105 (25.2) Percutaneous aspiration24 (6.2)37 (8.9) Other^f^5 (1.3)4 (1.0)[^5][^6][^7][^8][^9][^10][^11][^12]

Pathogens at Baseline {#s3b}
---------------------

The incidence and distribution of baseline pathogens were similar between the treatment groups. The most common gram-negative aerobes isolated at baseline from intra-abdominal specimens in the MITT population were *Escherichia coli* (525/806 \[65.1%\]), *Klebsiella pneumoniae* (76/806 \[9.4%\]), and *P. aeruginosa* (72/806 \[8.9%\]). The majority of infections were polymicrobial (257/389 \[66.1%\] and 288/417 \[69.1%\] patients in the ceftolozane/tazobactam plus metronidazole and meropenem treatment groups, respectively). There were 29 ESBL-producing Enterobacteriaceae isolated in each treatment group, an overall rate of 7.2% (58/806). Of 52 individual *P. aeruginosa* isolates for which MIC data were available, 3 (5.8%) isolates were resistant to ≥3 drug classes known to be active against *P. aeruginosa*, and 6 (11.5%) were nonsusceptible to ≥3 antipseudomonal drug classes.

The MIC required to inhibit the growth of 90% (MIC~90~) of Enterobacteriaceae was 1 mg/L for ceftolozane/tazobactam and 0.063 mg/L for meropenem. For *P. aeruginosa*, the MIC~90~ values for each study drug were 1 mg/L and 2 mg/L, respectively. Susceptibility rates to ceftolozane/tazobactam and meropenem were 97.4% and 99.9% for Enterobacteriaceae and 98.6% and 89.9% for *P. aeruginosa*, respectively.

Source Control Review Panel Findings {#s3c}
------------------------------------

The surgical review panel reviewed 73 patients. Twenty-four patients (12 in each treatment group) were considered to have had inadequate source control and were excluded from the CE and ME populations. Of the 9 patients who were considered to have obtained clinical cure by the investigator but required a second procedure, the surgical review panel changed 2 patients\' outcomes (1 per treatment arm) from cure to failure because of evidence of ongoing infection at the time of the second intervention.

Efficacy Analysis {#s3d}
-----------------

For the primary endpoint, clinical cure rates were 83.0% (323/389) with ceftolozane/tazobactam plus metronidazole and 87.3% (364/417) with meropenem in the MITT population at the TOC visit, which occurred at a median of 27 days (interquartile range, 26--28 days) after the TOC visit. The weighted difference in clinical cure rates (ceftolozane/tazobactam plus metronidazole minus meropenem) was −4.2% with a 2-sided 95% CI of −8.91% to .54%, thus meeting the statistical criteria for noninferiority. Statistical noninferiority was also demonstrated for the ME population, where clinical cure rates were 94.2% and 94.7% (weighted difference, −1.0; 95% CI, −4.52 to 2.59) at the TOC visit (Figure [2](#CIV097F2){ref-type="fig"}). Clinical cure rates in the ITT population at TOC were 83.6% for ceftolozane/tazobactam plus metronidazole and 86.2% for meropenem (difference, −2.6; 95% CI, −7.08 to 1.87), similar to those observed in the MITT population. In the CE population, cure rates were 94.1% and 94.0%, respectively (difference, 0.1; 95% CI, −3.30 to 3.55). At the end of therapy, clinical cure rates in the MITT population were higher in both treatment groups: 89.2% for ceftolozane/tazobactam plus metronidazole and 92.3% for meropenem (difference, −3.1; 95% CI, −7.23 to .89). Figure 2.Primary and secondary analysis endpoints at the test-of-cure visit. In the microbiological intent-to-treat (MITT) population, a treatment failure approach was used, where indeterminate clinical responses were imputed as failures. In the microbiologically evaluable (ME) population, a data-as-observed approach was used, where indeterminate clinical responses were excluded from the analysis. Abbreviations: CI, confidence interval; NI, noninferiority margin.

In both treatment groups, 8.2% of patients in the MITT populations failed treatment at the TOC visit (Figure [2](#CIV097F2){ref-type="fig"}). The most common reasons for failure were persisting or recurrent abdominal infection requiring an additional intervention (2.8% of failures in the ceftolozane/tazobactam plus metronidazole group and 3.6% in the meropenem group) and the requirement for additional antibiotics for ongoing cIAI (3.3% and 2.6%, respectively, for each treatment group). Other reasons for failure were postsurgical wound infection and death due to cIAI.

Clinical outcomes in the subgroup analyses were generally consistent with the primary and secondary analyses, with no meaningful differences recorded between treatments. Clinical cure rates with both treatments were generally lower in high-risk patients (elderly patients and those with higher APACHE II scores, moderate renal impairment, or small bowel and colon infections) vs the overall ME population (Table [4](#CIV097TB4){ref-type="table"}). Table 4.Subgroup Analysis of Clinical Cure at the Test-of-Cure Visit (Microbiologically Evaluable Population)Clinical Cure\
no./No. (%)Ceftolozane/Tazobactam Plus Metronidazole (n = 275)Meropenem (n = 321)Percentage Difference (95% CI)Sex Male147/157 (93.6)182/189 (96.3)−2.7 (−7.97 to 2.05) Female112/118 (94.9)122/132 (92.4)2.5 (−4.04 to 8.91)Age, y 18--64206/214 (96.3)249/262 (95.0)1.2 (−2.80 to 5.03) 65--7430/35 (85.7)36/38 (94.7)−9.0 (−24.59 to 5.43) ≥7523/26 (88.5)19/21 (90.5)−2.0 (−20.76 to 18.79)Region Eastern Europe213/221 (96.4)239/247 (96.8)−0.4 (−4.10 to 3.12) Western Europe2/5 (40.0)7/11 (63.6)−23.6 (−58.95 to 22.86) North America8/11 (72.7)10/11 (90.9)−18.2 (−48.41 to 15.40) South America28/28 (100)40/42 (95.2)4.8 (−7.78 to 15.79) Rest of world8/10 (80.0)8/10 (80.0)0 (−34.14 to 34.14)APACHE II score \<10213/222 (95.9)262/274 (95.6)0.3 (−3.61 to 3.98) ≥1045/52 (86.5)42/47 (89.4)−2.8 (−16.08 to 10.92)Baseline CrCl, mL/min \<508/11 (72.7)5/7 (71.4)1.3 (−34.37 to 40.92) ≥50251/264 (95.1)299/314 (95.2)−0.1 (−3.95 to 3.43)Prior antibiotic use Yes133/145 (91.7)163/177 (92.1)−0.4 (−6.81 to 5.69) No126/130 (96.9)141/144 (97.9)−1.0 (−5.76 to 3.30)Primary site of infection Bowel (small or large)35/43 (81.4)51/57 (89.5)−8.1 (−23.17 to 5.74) Other site of IAI224/232 (96.6)253/264 (95.8)0.7 (−2.97 to 4.28)Anatomic site of infection Appendix136/141 (96.5)172/179 (96.1)0.4 (−4.55 to 4.79) Nonappendix123/134 (91.8)132/142 (93.0)−1.2 (−7.86 to 5.33) Biliary--cholangitis1/1 (100)0/0NC Biliary--cholecystitis49/50 (98.0)43/46 (93.5)4.5 (−4.99 to 15.63) Colon25/31 (80.6)39/42 (92.9)−12.2 (−29.77 to 3.41) Parenchymal (liver)9/10 (90.0)8/8 (100)−10.0 (−40.42 to 23.46) Parenchymal (spleen)2/2 (100)1/1 (100)0 (−65.76 to 79.35) Small bowel11/13 (84.6)12/15 (80.0)4.6 (−25.20 to 32.12) Stomach/duodenum28/30 (93.3)26/26 (100)−6.7 (−21.32 to 7.08) Other5/5 (100)5/6 (83.3)16.7 (−28.88 to 56.35)Peritonitis type Localized126/132 (95.5)152/161 (94.4)1.0 (−4.62 to 6.34) Diffuse98/104 (94.2)108/114 (94.7)−0.5 (−7.37 to 6.02)No. of abscesses Single116/124 (93.5)146/152 (96.1)−2.5 (−8.65 to 2.90) Multiple22/25 (88.0)23/25 (92.0)−4.0 (−22.86 to 14.69)Procedure type Percutaneous aspiration14/14 (100)23/23 (100)0 (−21.53 to 14.31) Laparoscopy63/66 (95.5)73/81 (90.1)5.3 (−3.98 to 14.27) Laparotomy181/193 (93.8)207/217 (95.4)−1.6 (−6.42 to 2.90)[^13][^14]

Per-pathogen clinical cure rates were similar between groups ([Supplementary Table 2](http://cid.oxfordjournals.org/lookup/suppl/doi:10.1093/cid/civ097/-/DC1)). In all patients with ESBL-producing Enterobacteriaceae, the clinical cure rate was 95.8% (23/24) in the ceftolozane/tazobactam plus metronidazole group and 88.5% (23/26) in the meropenem group ([Supplementary Figure](http://cid.oxfordjournals.org/lookup/suppl/doi:10.1093/cid/civ097/-/DC1)). In patients with CTX-M-14/15 ESBL-producing Enterobacteriaceae, clinical cure was observed in 13 of 13 (100%) and 8 of 11 (72.7%) patients, respectively.

Safety {#s3e}
------

The incidence of AEs that developed during treatment was similar between the ceftolozane/tazobactam plus metronidazole group and the meropenem group (44.0% and 42.7%, respectively), and most events were mild to moderate in severity. The AEs occurring in ≥2% of patients in either treatment group are shown in Table [5](#CIV097TB5){ref-type="table"}. The most common laboratory AEs were increased alanine aminotransferase and aspartate aminotransferase, which occurred in 2.5% and 1.6% of all patients, respectively. Drug-related AEs leading to discontinuation were few, occurring in 3 patients (0.6%) in the ceftolozane/tazobactam plus metronidazole group and 4 patients (0.8%) in the meropenem group. Table 5.Adverse Events Occurring in ≥2% of Patients in Either Treatment Group (Safety Population)Adverse Event\
No. (%)Ceftolozane/Tazobactam Plus Metronidazole (n = 482)Meropenem (n = 497)Any adverse event212 (44.0)212 (42.7)Nausea38 (7.9)29 (5.8)Diarrhea30 (6.2)25 (5.0)Vomiting16 (3.3)20 (4.0)Pyrexia25 (5.2)20 (4.0)Hypokalemia14 (2.9)8 (1.6)Insomnia17 (3.5)11 (2.2)Headache12 (2.5)9 (1.8)Anemia, postoperative10 (2.1)8 (1.6)Hypertension9 (1.9)10 (2.0)

Serious AEs occurred in 39 of 482 (8.1%) and 36 of 497 (7.2%) patients in the ceftolozane/tazobactam plus metronidazole and meropenem groups, respectively. Drug-related serious AEs occurred in 1 patient in each treatment group (both *Clostridium difficile* infection).

There were 11 deaths (2.3%) in the ceftolozane/tazobactam plus metronidazole group and 8 deaths (1.6%) in the meropenem group; no death was considered by the investigators to be related to study treatment.

DISCUSSION {#s4}
==========

The increasing prevalence of multidrug-resistant, gram-negative organisms in serious infections is an important concern, and has led to the development of new therapeutic agents \[[@CIV097C19], [@CIV097C27], [@CIV097C28]\]. In this trial, the efficacy and safety of the novel antimicrobial agent ceftolozane/tazobactam were evaluated in patients with mostly community-acquired cIAIs. One-fifth of patients were aged ≥65 years, one-third had renal impairment, \>80% had peritonitis, and the most frequent site of infection was the appendix. These factors attest to the high degree of illness severity in the patients who were enrolled in this trial. Although the microbiology of infecting pathogens was similar to that observed in other phase 3 studies in this indication \[[@CIV097C29]--[@CIV097C32]\], the overall rate of infection with ESBL-positive isolates (7.2%) was higher than in previous observations \[[@CIV097C29], [@CIV097C30]\]. The key finding from this study was that intravenous ceftolozane/tazobactam (1.5 g) plus metronidazole (500 mg) every 8 hours was noninferior to the comparator treatment, intravenous meropenem (1 g) every 8 hours, when administered for 4--14 days for the treatment of cIAIs.

Ceftolozane/tazobactam plus metronidazole demonstrated high clinical cure rates in patients infected with the common cIAI pathogens including *E. coli, K. pneumoniae, P. aeruginosa, Enterobacter cloacae*, and *Klebsiella* *oxytoca*, as well as *Streptococcus anginosus*, *Streptococcus constellatus*, and *Streptococcus salivarius*.

As with other cephalosporins \[[@CIV097C31], [@CIV097C33]--[@CIV097C35]\], the AEs reported most frequently were gastrointestinal symptoms of nausea, vomiting, and diarrhea and are expected events in a postoperative population with cIAI.

Activity Against Extended-Spectrum β-Lactamases {#s4a}
-----------------------------------------------

In the past 10 years, ESBL-producing Enterobacteriaceae have become an important challenge for antibiotic treatment of infections, and ESBL carriage rates are increasing in nearly all geographic areas \[[@CIV097C36]\]. In the United States, up to 19% of healthcare-associated infections are due to ESBL-producing Enterobacteriaceae, constituting a serious threat of resistance \[[@CIV097C37]\]. For severe ESBL infections, carbapenems have become the drugs of choice \[[@CIV097C38]\].

Ceftolozane/tazobactam showed substantial clinical and microbiological activity against ESBL-producing *E. coli* and *Klebsiella* strains. The ESBL-positive rate is consistent with observations from the Study for Monitoring Antimicrobial Resistance Trends, a global surveillance program of gram-negative bacilli from IAIs. This European study characterized \>3000 patient isolates in 2008, revealing ESBL rates of 11.6% in *E. coli* and 17.9% in *K. pneumoniae* \[[@CIV097C39]\].

CTX-M--type ESBLs are by far the most common ESBLs worldwide, and are often associated with multidrug resistance in Enterobacteriaceae \[[@CIV097C11], [@CIV097C36]\]. In our study, more than one-half of the ESBL-producing Enterobacteriaceae isolated at baseline were positive for CTX-M-14 or CTX-M-15--type enzymes, but no *K. pneumoniae* carbapenemase enzymes were identified. Ceftolozane/tazobactam plus metronidazole maintained clinical efficacy against these highly resistant strains (100%) compared with 72.7% with meropenem.

Activity Against *Pseudomonas aeruginosa* {#s4b}
-----------------------------------------

Multidrug-resistant *P. aeruginosa* often requires complex antimicrobial regimens and, when treated inadequately, infections caused by this pathogen are associated with particularly poor outcomes including postoperative complications, longer hospital stays, and increased mortality \[[@CIV097C5], [@CIV097C6], [@CIV097C40]--[@CIV097C42]\]. In vitro studies have shown that ceftolozane/tazobactam is the most potent antipseudomonal agent, maintaining activity against many multidrug-resistant strains \[[@CIV097C13]\]. Ceftolozane/tazobactam demonstrated efficacy against *P. aeruginosa*, even though experience with multidrug-resistant *P. aeruginosa* was limited.

In conclusion, these results suggest that ceftolozane/tazobactam plus metronidazole is a potential alternative to the currently recommended antimicrobials for the treatment of cIAIs, especially when resistant Enterobacteriaceae or *P. aeruginosa* are suspected, such as in healthcare-associated infections.

Supplementary Data {#s5}
==================

[Supplementary materials](http://cid.oxfordjournals.org/lookup/suppl/doi:10.1093/cid/civ097/-/DC1) are available at *Clinical Infectious Diseases* online (<http://cid.oxfordjournals.org>). Supplementary materials consist of data provided by the author that are published to benefit the reader. The posted materials are not copyedited. The contents of all supplementary data are the sole responsibility of the authors. Questions or messages regarding errors should be addressed to the author.
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[^1]: Present affiliation: Achaogen Inc., South San Francisco, California.

[^2]: ^a^ Patients were not eligible for extension of treatment beyond 10 days.

[^3]: Abbreviations: APACHE, Acute Physiology and Chronic Health Evaluation; SD, standard deviation.

[^4]: ^a^ Data missing in 1 patient.

[^5]: Percentages are calculated as 100 × (no.*/*No.), except where indicated by a footnote.

[^6]: Abbreviation: IAI, intra-abdominal infection.

[^7]: ^a^ Investigator could choose \>1 site; totals are not mutually exclusive.

[^8]: ^b^ Investigator could chose only 1 diagnosis.

[^9]: ^c^ Percentages are calculated 100 × (no./No. of patients with abscess present).

[^10]: ^d^ Percentages are calculated 100 × (no./No. of patients with peritonitis present).

[^11]: ^e^ Patients could have multiple procedure types.

[^12]: ^f^ Other procedures included appendectomy and esophagogastroduodenoscopy.

[^13]: Regions are defined as follows: Eastern Europe (Bulgaria, Croatia, Estonia, Georgia, Hungary, Latvia, Lithuania, Poland, Republic of Moldova, Romania, Russia, Serbia, Slovakia, Ukraine); Western Europe (Belgium, Germany, Spain); North America (Mexico, United States); South America (Argentina, Brazil, Chile, Colombia, Peru); and rest of world (Australia, Israel, South Africa, South Korea).

[^14]: Abbreviations: APACHE, Acute Physiology and Chronic Health Evaluation; CI, confidence interval; CrCl, creatinine clearance; IAI, intra-abdominal infection; NC, not calculated.
